BSEM Fast-Tracks Nasdaq Uplisting

What investors need to know

April 07, 2026

*together with BioStem Technologies, Inc.

BioStem Technologies (BSEM) Rockets Toward Nasdaq with Record Earnings, Transformational $40M Acquisition, and High-Margin Growth Signaling a $25.50 Upside!

BioStem Technologies, Inc. (OTCQB: BSEM) is turning heads in the regenerative medicine space with seven consecutive profitable quarters, blockbuster gross margins hitting 97%, and a bold $40 million acquisition of BioTissue Holdings’ surgical and wound care business. 

This move instantly expands BSEM’s footprint into higher-acuity care—hospitals, outpatient centers, and ambulatory surgery facilities—while adding established products like Neox® and Clarix®. The acquisition contributes nearly $29 million in revenue from 2025 alone, diversifying the company’s revenue streams and positioning it for a major growth phase in 2026.

Beyond strategic expansion, BSEM continues to deliver robust earnings performance. Despite transitional macro pressures and one-time GAAP adjustments, quarterly revenue reached $10.1 million, adjusted EBITDA stayed positive at $3.4 million, and cash remained strong at ~$16 million post-acquisition. 

With Nasdaq uplisting preparations well underway, including audited 2024–2025 financials and KPMG review, the company is primed to attract institutional investors, improve liquidity, and unlock higher valuation multiples. Analysts see upside to $25.50, highlighting BSEM’s rare combination of profitability, clinical validation, and now expanded commercial reach.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Sideways Frequency) for this one day program on 4/07/26 for marketing efforts to increase public awareness of BioStem Technologies, Inc. (OTCQB: BSEM) .  SV may have also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.